Meeting
2022 ASCO Genitourinary Cancers Symposium
Attamage-A1: Phase I/II study of autologous CD8+ and CD4+ transgenic t cells expressing high affinity MAGE-A1-specific T-cell receptor (TCR) combined with anti-PD(L)1 in patients with metastatic MAGE-A1 expressing cancer.
Authors
Michael Thomas Schweizer
University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA
Michael Thomas Schweizer , Ted Gooley , Sylvia Lee , William R Gwin III, Monica Dherin , Megan Hickner , Jennifer Casserd , Megan McAfee , Thomas Schmitt , Cecilia CS Yeung , Vijayakrishna K. Gadi , Aude Chapuis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04639245
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr TPS592)
DOI
10.1200/JCO.2022.40.6_suppl.TPS592
Abstract #
TPS592
Poster Bd #
M9
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors.
First Author: Marcelo Vailati Negrao
Poster
2017 ASCO Annual Meeting
Two phase I/II open label clinical trials evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 or MAGE-A10 in subjects with stage IIIb or stage IV non-small cell lung cancer (NCT02588612/NCT02592577).
First Author: Ben C. Creelan
Poster
2023 ASCO Annual Meeting
Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).
First Author: Rosa Nadal
Poster
2017 ASCO Annual Meeting
A phase I/II clinical trial of E6 T-cell receptor gene therapy for human papillomavirus (HPV)-associated epithelial cancers.
First Author: Christian S. Hinrichs